A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.

NCT06130007 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Oral Squamous Cell Carcinoma

Interventions

DRUG: Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy

Sponsor

Xuekui Liu